Educational only. Not medical advice.
A viral post this week announced that the "first ever" CRISPR gene-editing treatment has been injected into humans to rewrite DNA and overcome a degenerative liver disease. There is real news behind it, but "first ever" is not accurate. This guide sorts out what happened, what it means and what is still unknown.
The news behind the post
Prime Medicine announced that the first patient has been dosed in a global Phase 1/2 clinical trial of PM577a, an investigational therapy for Wilson disease caused by the H1069Q mutation. The announcement appeared in early October, and CRISPR news roundups repeated it in the days that followed.
- The disease: Wilson disease is a rare, progressive genetic disorder of copper transport caused by loss-of-function mutations in the ATP7B gene. Copper builds up in the liver and can also damage the brain, kidneys and cornea. Current treatments, copper chelators and zinc salts, manage it but do not cure it and must be taken for life. A liver transplant is the only curative option.
- The therapy: PM577a is an in vivo prime editor delivered in lipid nanoparticles (LNPs) as a single intravenous infusion. It is designed to correct the H1069Q mutation in liver cells. H1069Q is the most common Wilson disease mutation in North America and Europe.
- The trial: an open-label, first-in-human Phase 1/2 study (NCT07748403) in adults and adolescents with at least one H1069Q allele. It starts with clinically stable adults and tests ascending doses.
- The goals: safety and tolerability first, plus early signs of efficacy. Possible measures include copper handling, ceruloplasmin and urinary copper, and whether patients can eventually stop standard medicines.
- The timeline: the company expects initial clinical data in 2027.
Is it really the "first ever"?
No, not in the broad sense the post suggests. Gene editing given directly into the body has been tested in people for years. Intellia's CRISPR therapy for transthyretin amyloidosis was the first to be delivered by LNP into the bloodstream, and later trials have treated cholesterol disorders, hereditary angioedema and alpha-1 antitrypsin deficiency. Casgevy, an approved CRISPR therapy for sickle cell disease, edits cells outside the body.
What is new here is narrower. The company describes this as its own first clinical study of an in vivo prime editing therapy and the first test of its liver program. The announcement does not claim to be the first in vivo prime editing patient anywhere.
CRISPR vs prime editing: what "rewrite" means
Classic CRISPR-Cas9 works like molecular scissors. It cuts both strands of DNA and relies on the cell's repair machinery. Prime editing is a newer approach built on CRISPR components. It nicks only one strand and uses a template to write a specific small change directly into the DNA, with no double-strand break. That is why it is often described as "search and replace" or "rewriting." It is still early, and prime editing has far less human data than conventional CRISPR.
What is still unknown
- No safety or efficacy results have been reported.
- The number of patients and the sites have not been disclosed.
- Edits made in the liver are intended to be permanent, so long-term follow-up matters.
- Early results often do not predict later ones.
The company has said it hopes treatment could one day happen before irreversible liver and neurological damage. That is a goal, not a result.
How this differs from peptides
Gene editing and peptide medicines are very different things. Peptides are short chains of amino acids that signal or act in the body and are cleared over time. Gene editors change DNA, and the change is meant to last. Evidence standards also differ. Gene-editing therapies go through staged trials, close safety monitoring and years of follow-up, and that level of scrutiny is the right benchmark for any new therapy.
How to read "BREAKING" headlines
- Look for the word "first" and ask: first at what, and by whom?
- Check the phase. Phase 1 mainly tests safety.
- Look for results. Dosing a patient is not a finding.
- Find the primary source, such as the company release or the trial registry entry.
This article summarizes company announcements and news coverage and is not a substitute for primary sources. It is not medical advice. Talk to a licensed clinician about any treatment decision.
Sources: Prime Medicine announcement · CRISPR Medicine News weekly, 23 Oct 2026 · Innovative Genomics Institute: CRISPR Clinical Trials, 2026 Update
0 comments